Goldman Sachs on Spyre (SYRE): 'Initial SPY001 efficacy data bolsters confidence into remaining data readouts later this year'
Goldman Sachs analyst Paul CHoi reiterated an Early-Stage Biotech rating on Spyre (NASDAQ: SYRE).The analyst comments "Initial induction data both ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)